Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

42.60 -0.09 (-0.21%)
Streaming Delayed Price Updated: 1:51 PM EDT, Jul 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,251,615
Open 43.80
Bid (Size) 42.57 (200)
Ask (Size) 42.62 (100)
Prev. Close 42.69
Today's Range 42.01 - 44.38
52wk Range 41.73 - 104.32
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
From Tempus AI, Inc
Via Business Wire
News headline image
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition ↗
Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma... 
Via MarketBeat
Topics Artificial Intelligence

Performance

YTD
-31.7%
-31.7%
1 Month
-24.1%
-24.1%
3 Month
-19.1%
-19.1%
6 Month
-37.0%
-37.0%
1 Year
-31.3%
-31.3%

More News

Read More
News headline image
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
From Tempus
Via Business Wire
News headline image
Tempus to Report Second Quarter 2026 Financial Results on July 30
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
From Tempus AI, Inc.
Via Business Wire
News headline image
Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing
From Ambry Genetics
Via Business Wire
News headline image
Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
Why Tempus AI Stock Is Surging On Thursday? ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
From Tempus AI, Inc.
Via Business Wire
News headline image
What to Know About This Fund's $32.6 Million Porch Group Purchase ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
From Tempus AI, Inc.
Via Business Wire
News headline image
Why Is Tempus AI Stock Surging On Thursday? ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
From Tempus AI, Inc.
Via Business Wire

Frequently Asked Questions

Is Tempus AI, Inc. - Class A Common Stock publicly traded?
Yes, Tempus AI, Inc. - Class A Common Stock is publicly traded.
What exchange does Tempus AI, Inc. - Class A Common Stock trade on?
Tempus AI, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tempus AI, Inc. - Class A Common Stock?
The ticker symbol for Tempus AI, Inc. - Class A Common Stock is TEM on the Nasdaq Stock Market
What is the current price of Tempus AI, Inc. - Class A Common Stock?
The current price of Tempus AI, Inc. - Class A Common Stock is 42.60
When was Tempus AI, Inc. - Class A Common Stock last traded?
The last trade of Tempus AI, Inc. - Class A Common Stock was at 07/27/26 01:51 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.